Novo Nordisk, a Danish pharmaceutical company, is capitalising on the obesity epidemic with its weight-loss drug, Ozempic. The medication, originally designed to treat diabetes, has demonstrated substantial weight-loss benefits, causing a surge in its popularity. Novo Nordisk’s marketing strategy involves both direct-to-consumer advertising and lobbying physicians to prescribe the drug.
Despite the potential benefits, Ozempic has sparked controversy due to its high cost. A year’s supply can cost up to $36,000, making it unaffordable for many. Critics argue that the drug’s price tag is a barrier to addressing the obesity epidemic at a societal level.
Meanwhile, Novo Nordisk is not the only pharmaceutical company profiting from the obesity crisis. Companies like Eli Lilly and Pfizer are also developing weight-loss drugs, further fuelling the burgeoning market.
This trend underscores the broader issue of the pharmaceutical industry’s role in addressing public health crises. While life-saving medications are essential, the high costs and profit-driven nature of the industry raise ethical questions. As obesity rates continue to rise, the debate over the pricing and accessibility of weight-loss drugs is set to intensify.
Go to source article: https://www.profgalloway.com/corporate-ozempic/